ClinicalTrials.gg
CompletedNCT02547935Updated Aug 21, 2019Results posted

A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD

A Phase 2/3 interventional study of Dapagliflozin 10 mg and Saxagliptin 2.5 mg in Type 2 Diabetes Mellitus, CKD and Albuminuria, sponsored by AstraZeneca. Completed at 112 sites in 9 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2019-08-21.

Sponsored by AstraZeneca · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
459
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 — 15 open to participants now, 19 under way, 5 of them phase 3. dapagliflozin · Diabetes Mellitus, Type 2.

Enrollment
36th of 180
459 · median 82
Started
2015
with 14 others
Phase 2/3
6 of 180
none open now
Registered
66th of 180
by date
Lead sponsor
72 of 180
AstraZeneca

Among the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, this one is the 36th largest by enrollment, is one of 15 that started in 2015, is one of 6 in phase 2/3, and was the 66th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

15 of the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About dapagliflozin

dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this clinical research study is to determine whether dapagliflozin alone or in combination with saxagliptin can decrease albuminuria and improve glycemic control in patients with Type 2 diabetes, albuminuria and renal impairment (CKD). The study is planned to randomize a total of 450 patients (150 patients per treatment arm)

03

Conditions studied

  • Type 2 Diabetes Mellitus, CKD and Albuminuria
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of prior to any study specific procedures
  • Female or male aged ≥18 years
  • History of type 2 diabetes mellitus for more than 12 months
  • ≥7.0% and ≤11.0%
  • Stable antidiabetic treatment during the last 12 weeks up to randomization
  • 25-75 mL/minute/1.73m2, inclusive
  • Micro or macroalbuminuria (UACR 30 - 3500 mg/g)
  • Treatment with ACE inhibitor or an ARB for at least 3 months prior to screening
  • between 20 and 45 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Any of the following CV/Vascular Diseases within 3 month prior to signing the consent at Visit 1:

    • Myocardial infarction
    • cardiac surgery or revascularization (CABG/PTCA)
    • unstable angina
    • unstable HF
    • (NYHA) Class III-IV
    • (TIA) or significant cerebrovascular disease
    • unstable or previously undiagnosed arrhythmia
  • Significant hepatic disease, including, but not limited to, chronic active hepatitis and/or severe hepatic insufficiency
  • (AST) or Alanine Aminotransferase (ALT) > 3X
  • Total (TB) >2 mg/dL (34.2 μmol/L)
  • History of acute kidney injury requiring renal replacement therapy (dialysis or ultrafiltration) or any or imaging verifying intercurrent kidney disease other than diabetic nephropathy or diabetic nephropathy with nephrosclerosis
  • Ongoing treatment with a SGLT2 inhibitor, GLP-1 agonist or DPP4 inhibitors
  • Any condition which, in the judgment of the Investigator, may render the patient unable to complete the study or which may pose a significant risk to the patient or patient suspected or with confirmed poor protocol or medication compliance
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
459 participants (actual)

Study arms

  • Experimental
    Dapagliflozin 10mg

    Tablets administered orally once daily for 24 weeks

    Drug: Dapagliflozin 10 mg

  • Experimental
    Dapagliflozin 10mg + Saxagliptin 2.5mg

    Tablets administered orally once daily for 24 weeks

    Drug: Saxagliptin 2.5 mg

  • Placebo comparator
    Placebo

    Tablets administered orally once daily for 24 weeks

    Drug: Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg

Interventions

  • Tablets administered orally once daily for 24 weeks.

    Also known as: Forxiga™

  • Tablets administered orally once daily for 24 weeks.

    Also known as: Onglyza™

  • DrugMatching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg

    Tablets administered orally once daily for 24 weeks.

06

What researchers measure

Primary outcomes

  1. Adjusted Mean Change From Baseline in Glycosylated Haemoglobin (HbA1c): Comparison of Dapagliflozin 10 mg Plus Saxagliptin 2.5 mg and Placebo at Week 24

    HbA1c was analysed at baseline and every 4 weeks during the 24-week treatment period. Only measurements prior to rescue or treatment discontinuation were analysed. The adjusted mean change from baseline at Week 24 was analysed using a mixed model repeated measures (MMRM) model.

    Time frame: Baseline and Week 24

  2. Adjusted Mean Percent Change From Baseline in Urine Albumin-to-Creatinine Ratio (UACR) at Week 24

    UACR was analysed at baseline and every 4 weeks during the 24-week treatment period. All measurements regardless of rescue medication or treatment discontinuation were analysed. UACR values were first transformed to logarithms and the results were based on exponentiation of model estimates and expressed as adjusted mean percent change from baseline at Week 24.

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Adjusted Mean Percent Change From Baseline in Total Body Weight at Week 24

    Total body weight was measured in kilograms (kg) at baseline and at Week 1 then every 4 weeks during the 24-week treatment period. All measurements regardless of rescue medication or treatment discontinuation were analysed. Total body weight values were first transformed to logarithms and the results were based on exponentiation of model estimates and expressed as adjusted mean percent change from baseline at Week 24.

    Time frame: Baseline and Week 24

  2. Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24

    FPG was analysed at baseline and Week 1 then every 4 weeks during the 24-week treatment period. Only measurements prior to rescue or treatment discontinuation were analysed. The adjusted mean change from baseline at Week 24 was analysed using a MMRM model.

    Time frame: Baseline and Week 24

  3. Percentage of Patients Achieving at Least 30% Reduction in UACR at Week 24

    The percentage of patients meeting the criteria of at least a 30% reduction in UACR, was analysed using a logistic regression model. If no measurement was available at Week 24 the last available post-baseline measurement was carried forward (Last Observation Carried Forward \[LOCF\]).

    Time frame: From baseline up to Week 24

  4. Percentage of Patients Achieving a Reduction in HbA1c of Less Than 7.0% at Week 24

    The percentage of patients meeting the criteria of a less than 7% reduction in HbA1c, was analysed using a logistic regression model. If no measurement was available at Week 24 the last available post-baseline measurement was carried forward (LOCF). Only measurements prior to rescue or treatment discontinuation were analysed.

    Time frame: From baseline to Week 24

  5. Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure (SBP) at Week 24

    Seated SBP was analysed at baseline, Week 1 and every 4 weeks during the 24-week treatment period. All measurements regardless of rescue medication or treatment discontinuation were analysed. The adjusted mean change from baseline at Week 24 was analysed using a MMRM model.

    Time frame: Baseline and Week 24

  6. Adjusted Mean Change From Baseline in HbA1c: Comparison of Dapagliflozin 10 mg and Placebo at Week 24

    HbA1c was analysed at baseline and every 4 weeks during the 24-week treatment period. Only measurements prior to rescue or treatment discontinuation were analysed. The adjusted mean change from baseline at Week 24 was analysed using a MMRM model.

    Time frame: Baseline and Week 24

07

Results

Posted Jun 4, 2019
Limitations and caveats
Anomalous data at 1 site was identified following completion of the study. All data from this site were excluded from the full analysis following an audit; the findings led the sponsor to believe the site did not comply with the principles of GCP.

Participant flow

Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus with micro- or macro-albuminuria and treated with ACEi or ARB were enrolled into an international, multi-centre study from 21 Sep 2015. The last patient's last visit was 18 May 2018.

Participant flow — Overall Study
MilestoneDapagliflozin 10 mg + Saxagliptin 2.5 mgDapagliflozin 10 mgPlacebo
Started155145148
Received treatment152145148
Full analysis set152144148
Safety analysis set152145148
Completed150137143
Not completed585
Withdrew: Other010
Withdrew: Withdrawal by subject234
Withdrew: Screen failure200
Withdrew: Physician decision010
Withdrew: Lost to follow-up021
Withdrew: Death110

Outcome measures

PrimaryAdjusted Mean Change From Baseline in Glycosylated Haemoglobin (HbA1c): Comparison of Dapagliflozin 10 mg Plus Saxagliptin 2.5 mg and Placebo at Week 24

HbA1c was analysed at baseline and every 4 weeks during the 24-week treatment period. Only measurements prior to rescue or treatment discontinuation were analysed. The adjusted mean change from baseline at Week 24 was analysed using a mixed model repeated measures (MMRM) model.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Percentage of Glycoslyated HbA1c
Adjusted Mean Change From Baseline in Glycosylated Haemoglobin (HbA1c): Comparison of Dapagliflozin 10 mg Plus Saxagliptin 2.5 mg and Placebo at Week 24
Percentage of Glycoslyated HbA1cDapagliflozin 10 mg + Saxagliptin 2.5 mgPlacebo
Adjusted Mean Change From Baseline in Glycosylated Haemoglobin (HbA1c): Comparison of Dapagliflozin 10 mg Plus Saxagliptin 2.5 mg and Placebo at Week 24-0.85 ± 0.09-0.27 ± 0.09
Statistical analysis
  • Dapagliflozin 10 mg + Saxagliptin 2.5 mg vs Placebo · MMRM · p = <0.001 (Statistical significance level = 0.025.) · Difference in adjusted mean change: -0.58 · 95% CI -0.80 to -0.37
PrimaryAdjusted Mean Percent Change From Baseline in Urine Albumin-to-Creatinine Ratio (UACR) at Week 24

UACR was analysed at baseline and every 4 weeks during the 24-week treatment period. All measurements regardless of rescue medication or treatment discontinuation were analysed. UACR values were first transformed to logarithms and the results were based on exponentiation of model estimates and expressed as adjusted mean percent change from baseline at Week 24.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Percent change
Adjusted Mean Percent Change From Baseline in Urine Albumin-to-Creatinine Ratio (UACR) at Week 24
Percent changeDapagliflozin 10 mg + Saxagliptin 2.5 mgDapagliflozin 10 mgPlacebo
Adjusted Mean Percent Change From Baseline in Urine Albumin-to-Creatinine Ratio (UACR) at Week 24-39.1 ± 5.1-22.4 ± 6.6-1.8 ± 8.3
Statistical analysis
  • Dapagliflozin 10 mg + Saxagliptin 2.5 mg vs Placebo · MMRM · p = <0.001 (Statistical significance level = 0.025.) · Difference in adjusted mean change: -38.0 · 95% CI -48.2 to -25.8
  • Dapagliflozin 10 mg vs Placebo · MMRM · p = 0.011 (Statistical significance level = 0.025.) · Difference in adjusted mean change: -21.0 · 95% CI -34.1 to -5.2
SecondaryAdjusted Mean Percent Change From Baseline in Total Body Weight at Week 24

Total body weight was measured in kilograms (kg) at baseline and at Week 1 then every 4 weeks during the 24-week treatment period. All measurements regardless of rescue medication or treatment discontinuation were analysed. Total body weight values were first transformed to logarithms and the results were based on exponentiation of model estimates and expressed as adjusted mean percent change from baseline at Week 24.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Percent change
Adjusted Mean Percent Change From Baseline in Total Body Weight at Week 24
Percent changeDapagliflozin 10 mg + Saxagliptin 2.5 mgDapagliflozin 10 mgPlacebo
Adjusted Mean Percent Change From Baseline in Total Body Weight at Week 24-0.65 ± 0.55-1.48 ± 0.56-0.61 ± 0.56
Statistical analysis
  • Dapagliflozin 10 mg + Saxagliptin 2.5 mg vs Placebo · MMRM · p = 0.953 (Statistical significance level = 0.025.) · Difference in adjusted mean change: -0.04 · 95% CI -1.32 to 1.26
  • Dapagliflozin 10 mg vs Placebo · MMRM · p = 0.193 (Statistical significance level = 0.025.) · Difference in adjusted mean change: -0.87 · 95% CI -2.17 to 0.44
SecondaryAdjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24

FPG was analysed at baseline and Week 1 then every 4 weeks during the 24-week treatment period. Only measurements prior to rescue or treatment discontinuation were analysed. The adjusted mean change from baseline at Week 24 was analysed using a MMRM model.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · mg/decilitre (dL)
Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24
mg/decilitre (dL)Dapagliflozin 10 mg + Saxagliptin 2.5 mgDapagliflozin 10 mgPlacebo
Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24-17.2 ± 5.2-13.1 ± 5.4-11.2 ± 5.5
Statistical analysis
  • Dapagliflozin 10 mg + Saxagliptin 2.5 mg vs Placebo · MMRM · p = 0.298 (Statistical significance level = 0.025.) · Difference in adjusted mean change: -6.1 · 95% CI -17.5 to 5.4
  • Dapagliflozin 10 mg vs Placebo · MMRM · p = 0.746 (Statistical significance level = 0.025.) · Difference in adjusted mean change: -1.9 · 95% CI -13.6 to 9.8
SecondaryPercentage of Patients Achieving at Least 30% Reduction in UACR at Week 24

The percentage of patients meeting the criteria of at least a 30% reduction in UACR, was analysed using a logistic regression model. If no measurement was available at Week 24 the last available post-baseline measurement was carried forward (Last Observation Carried Forward \[LOCF\]).

Time frame:
From baseline up to Week 24
Reported as:
Number · Percentage of patients
Percentage of Patients Achieving at Least 30% Reduction in UACR at Week 24
Percentage of patientsDapagliflozin 10 mg + Saxagliptin 2.5 mgDapagliflozin 10 mgPlacebo
Percentage of Patients Achieving at Least 30% Reduction in UACR at Week 2457.045.031.3
Statistical analysis
  • Dapagliflozin 10 mg + Saxagliptin 2.5 mg vs Placebo · Regression, Logistic · p = <0.001 (Statistical significance level = 0.025.) · Odds ratio (or): 2.98 · 95% CI 1.8 to 4.8
  • Dapagliflozin 10 mg vs Placebo · Regression, Logistic · p = 0.013 (Statistical significance level = 0.025.) · Odds ratio (or): 1.86 · 95% CI 1.1 to 3.0
SecondaryPercentage of Patients Achieving a Reduction in HbA1c of Less Than 7.0% at Week 24

The percentage of patients meeting the criteria of a less than 7% reduction in HbA1c, was analysed using a logistic regression model. If no measurement was available at Week 24 the last available post-baseline measurement was carried forward (LOCF). Only measurements prior to rescue or treatment discontinuation were analysed.

Time frame:
From baseline to Week 24
Reported as:
Number · Percentage of patients
Percentage of Patients Achieving a Reduction in HbA1c of Less Than 7.0% at Week 24
Percentage of patientsDapagliflozin 10 mg + Saxagliptin 2.5 mgDapagliflozin 10 mgPlacebo
Percentage of Patients Achieving a Reduction in HbA1c of Less Than 7.0% at Week 2435.115.010.3
Statistical analysis
  • Dapagliflozin 10 mg + Saxagliptin 2.5 mg vs Placebo · Regression, Logistic · p = <0.001 (Statistical significance level = 0.025.) · Odds ratio (or): 5.43 · 95% CI 2.6 to 11.2
  • Dapagliflozin 10 mg vs Placebo · Regression, Logistic · p = 0.167 (Statistical significance level = 0.025.) · Odds ratio (or): 1.74 · 95% CI 0.8 to 3.8
SecondaryAdjusted Mean Change From Baseline in Seated Systolic Blood Pressure (SBP) at Week 24

Seated SBP was analysed at baseline, Week 1 and every 4 weeks during the 24-week treatment period. All measurements regardless of rescue medication or treatment discontinuation were analysed. The adjusted mean change from baseline at Week 24 was analysed using a MMRM model.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Millimetre of mercury (mmHg)
Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure (SBP) at Week 24
Millimetre of mercury (mmHg)Dapagliflozin 10 mg + Saxagliptin 2.5 mgDapagliflozin 10 mgPlacebo
Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure (SBP) at Week 24-8.8 ± 1.6-6.9 ± 1.7-4.1 ± 1.7
Statistical analysis
  • Dapagliflozin 10 mg + Saxagliptin 2.5 mg vs Placebo · MMRM · p = 0.009 (Statistical significance level = 0.025.) · Difference in adjusted mean change: -4.8 · 95% CI -8.3 to -1.2
  • Dapagliflozin 10 mg vs Placebo · MMRM · p = 0.122 (Statistical significance level = 0.025.) · Difference in adjusted mean change: -2.8 · 95% CI -6.4 to 0.8
SecondaryAdjusted Mean Change From Baseline in HbA1c: Comparison of Dapagliflozin 10 mg and Placebo at Week 24

HbA1c was analysed at baseline and every 4 weeks during the 24-week treatment period. Only measurements prior to rescue or treatment discontinuation were analysed. The adjusted mean change from baseline at Week 24 was analysed using a MMRM model.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Percentage of Glycoslyated HbA1c
Adjusted Mean Change From Baseline in HbA1c: Comparison of Dapagliflozin 10 mg and Placebo at Week 24
Percentage of Glycoslyated HbA1cDapagliflozin 10 mgPlacebo
Adjusted Mean Change From Baseline in HbA1c: Comparison of Dapagliflozin 10 mg and Placebo at Week 24-0.43 ± 0.09-0.27 ± 0.09
Statistical analysis
  • Dapagliflozin 10 mg vs Placebo · MMRM · p = 0.142 (Statistical significance level = 0.025.) · Difference in adjusted mean change: -0.16 · 95% CI -0.38 to 0.05

Adverse events

Collected over Adverse events (AEs) are reported from Day 1 of the 24-week double-blind treatment period. Non-serious AEs were included up to the last day of double-blind treatment + 4 days. Serious AEs were included up to the last day of double-blind treatment + 30 days, giving a total maximum time frame of 28 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dapagliflozin 10 mg + Saxagliptin 2.5 mg1/152 (0.7%)12/152 (7.9%)12/152 (7.9%)
Dapagliflozin 10 mg1/145 (0.7%)12/145 (8.3%)18/145 (12.4%)
Placebo0/148 (0%)16/148 (10.8%)8/148 (5.4%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventDapagliflozin 10 mg + Saxagliptin 2.5 mgDapagliflozin 10 mgPlacebo
SyncopeNervous system disorders0/1522/1450/148
Angina pectorisCardiac disorders0/1521/1452/148
Myocardial infarctionCardiac disorders0/1520/1452/148
Ankle fractureInjury, poisoning and procedural complications0/1520/1452/148
Cerebrovascular accidentNervous system disorders0/1520/1452/148
Acute kidney injuryRenal and urinary disorders0/1520/1452/148
HypoglycaemiaMetabolism and nutrition disorders2/1520/1451/148
Cardiac failureCardiac disorders0/1521/1450/148
Ventricular extrasystolesCardiac disorders0/1521/1450/148
DiarrhoeaGastrointestinal disorders0/1521/1450/148
Most frequent other events
Most frequent other events
EventDapagliflozin 10 mg + Saxagliptin 2.5 mgDapagliflozin 10 mgPlacebo
NasopharyngitisInfections and infestations10/15210/1456/148
InfluenzaInfections and infestations2/1528/1452/148

Baseline characteristics

Baseline characteristics are presented for all randomised patients.

Age, Continuous
Age, Continuous(years)Dapagliflozin 10 mg + Saxagliptin 2.5 mgDapagliflozin 10 mgPlaceboTotal
Mean64.0 ± 9.2164.7 ± 8.6164.7 ± 8.5364.4 ± 8.78
Age, Customized
Age, Customized(Participants)Dapagliflozin 10 mg + Saxagliptin 2.5 mgDapagliflozin 10 mgPlaceboTotal
<65 years786468210
>=65 years778180238
Sex: Female, Male
Sex: Female, Male(Participants)Dapagliflozin 10 mg + Saxagliptin 2.5 mgDapagliflozin 10 mgPlaceboTotal
Female454343131
Male110102105317
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dapagliflozin 10 mg + Saxagliptin 2.5 mgDapagliflozin 10 mgPlaceboTotal
Hispanic or Latino423238112
Not Hispanic or Latino113113110336
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dapagliflozin 10 mg + Saxagliptin 2.5 mgDapagliflozin 10 mgPlaceboTotal
White775564196
Black or African American871126
Asian576753177
Native Hawaiian or other Pacific Islander1214
American Indian or Alaska Native0112
Other12131843
08

Study locations

112 sites
  • Research Site
    Peoria, Arizona 85381, United States
  • Research Site
    Chula Vista, California 91910, United States
  • Research Site
    Concord, California 94520, United States
  • Research Site
    El Centro, California 92243, United States
  • Research Site
    La Mesa, California 92123, United States
  • Research Site
    Long Beach, California 90807, United States
  • Research Site
    Los Gatos, California 95032, United States
  • Research Site
    North Hollywood, California 91606, United States
  • Research Site
    Riverside, California 92505, United States
  • Research Site
    San Diego, California 92111, United States
  • Research Site
    San Dimas, California 91773, United States
  • Research Site
    Hollywood, Florida 33024, United States
  • Research Site
    Miami, Florida 33126, United States
  • Research Site
    New Port Richey, Florida 34652, United States
  • Research Site
    Palm Harbor, Florida 34684, United States
  • Research Site
    Pompano Beach, Florida 33060, United States
  • Research Site
    Augusta, Georgia 30909, United States
  • Research Site
    Meridian, Idaho 83642, United States
  • Research Site
    Chicago, Illinois 60643, United States
  • Research Site
    Bangor, Maine 04401, United States
  • Research Site
    Kansas City, Missouri 64111, United States
  • Research Site
    Las Vegas, Nevada 89148, United States
  • Research Site
    Bronx, New York 10459, United States
  • Research Site
    Springfield Gardens, New York 11413, United States
  • Research Site
    Greensboro, North Carolina 27408, United States
  • Research Site
    Morehead City, North Carolina 28557, United States
  • Research Site
    Rocky Mount, North Carolina 27804, United States
  • Research Site
    Philadelphia, Pennsylvania 19107, United States
  • Research Site
    Greenville, South Carolina 29605, United States
  • Research Site
    Brownsville, Texas 78520, United States
  • Research Site
    Cypress, Texas 77429, United States
  • Research Site
    Houston, Texas 77004, United States
  • Research Site
    San Antonio, Texas 78215, United States
  • Research Site
    Sugar Land, Texas 77479, United States
  • Research Site
    Salt Lake City, Utah 84124, United States
  • Research Site
    Burke, Virginia 22015, United States
  • Research Site
    Richmond, Virginia 23219, United States
  • Research Site
    Box Hill, 3128, Australia
  • Research Site
    Campbelltown, 2560, Australia
  • Research Site
    Geelong, 3220, Australia
  • Research Site
    Herston, 4029, Australia
  • Research Site
    Winnipeg, Manitoba R3E 3P4, Canada
  • Research Site
    Moncton, New Brunswick E1G 1A7, Canada
  • Research Site
    Ajax, Ontario L1Z 0M1, Canada
  • Research Site
    Cambridge, Ontario N1R 6V6, Canada
  • Research Site
    Scarborough, Ontario M1H 3G4, Canada
  • Research Site
    Scarborough, Ontario M1R 3A6, Canada
  • Research Site
    Toronto, Ontario M5C 2T2, Canada
  • Research Site
    Chicoutimi, Quebec G7H 7K9, Canada
  • Research Site
    Saint-Jerome, Quebec J7Z 5T3, Canada
  • Research Site
    Sherbrooke, Quebec J1H 5N4, Canada
  • Research Site
    Quebec, G2J 0C4, Canada
  • Research Site
    Chuo-ku, 103-0002, Japan
  • Research Site
    Chuo-ku, 103-0027, Japan
  • Research Site
    Chuo-ku, 103-0028, Japan
  • Research Site
    Hachioji-shi, 192-0071, Japan
  • Research Site
    Higashiosaka-shi, 577-0803, Japan
  • Research Site
    Kisarazu-shi, 292-0038, Japan
  • Research Site
    Kyoto-shi, 615-8125, Japan
  • Research Site
    Neyagawa-shi, 572-0015, Japan
  • Research Site
    Nishinomiya-shi, 663-8113, Japan
  • Research Site
    Oita-shi, 870-0039, Japan
  • Research Site
    Osaka-shi, 530-0001, Japan
  • Research Site
    Osaka-shi, 559-0012, Japan
  • Research Site
    Sendai-shi, 980-0021, Japan
  • Research Site
    Shinjuku-ku, 160-0008, Japan
  • Research Site
    Toyonaka-shi, 560-0082, Japan
  • Research Site
    Ansan-si, 15355, Korea, Republic of
  • Research Site
    Busan, 47392, Korea, Republic of
  • Research Site
    Cheongju-si, 28644, Korea, Republic of
  • Research Site
    Daejeon, 35015, Korea, Republic of
  • Research Site
    Seongnam-si, 13620, Korea, Republic of
  • Research Site
    Seoul, 02841, Korea, Republic of
  • Research Site
    Seoul, 03080, Korea, Republic of
  • Research Site
    Seoul, 06351, Korea, Republic of
  • Research Site
    Suwon-si, 16499, Korea, Republic of
  • Research Site
    Wonju-si, 26426, Korea, Republic of
  • Research Site
    Aguascalientes, 20230, Mexico
  • Research Site
    Guadalajara, 44160, Mexico
  • Research Site
    Guadalajara, 44600, Mexico
  • Research Site
    Guadalajara, 44670, Mexico
  • Research Site
    Mexico, 03800, Mexico
  • Research Site
    Mexico, 06726, Mexico
  • Research Site
    Monterey, 64060, Mexico
  • Research Site
    Monterrey, 64460, Mexico
  • Research Site
    Monterrey, 64465, Mexico
  • Research Site
    México, 03300, Mexico
  • Research Site
    Queretaro, 76000, Mexico
  • Research Site
    Zapopan, Jalisco, 45200, Mexico
  • Research Site
    Zapopan, 45116, Mexico
  • Research Site
    Benoni, 1501, South Africa
  • Research Site
    Cape Town, 1730, South Africa
  • Research Site
    Cape Town, 7925, South Africa
  • Research Site
    Durban, 4092, South Africa
  • Research Site
    Kuilsrivier, 7580, South Africa
  • Research Site
    Mamelodi East, 0184, South Africa
  • Research Site
    Muckleneuk, 0002, South Africa
  • Research Site
    Paarl, 7646, South Africa
  • Research Site
    Pretoria, 184, South Africa
  • Research Site
    A Coruña, 15006, Spain

Showing the first 100 of 112 sites across 9 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Pollock C, Stefansson B, Reyner D, Rossing P, Sjostrom CD, Wheeler DC, Langkilde AM, Heerspink HJL. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019 Jun;7(6):429-441. doi: 10.1016/S2213-8587(19)30086-5. Epub 2019 Apr 13. PubMed 30992195 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2015 to primary completion in May 2018, 31 months.

Results were first posted in Jun 2019, 1 year after primary completion.

Of 32 phase 2/3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 31. This study's 31 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2015
First posted
Sep 14, 2015
StartActual
Sep 21, 2015
Primary completionActual
May 18, 2018
CompletionActual
May 18, 2018
Results first posted
Jun 4, 2019
Last update
Aug 21, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02547935
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 14, 2015
Start date
Sep 21, 2015
Primary completion
May 18, 2018
Completion
May 18, 2018
Results posted
Jun 4, 2019
Last update
Aug 21, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dapagliflozin · Saxagliptin

Start the discussion